Detail akcie Pharmena online

Business Summary: Pharmena SA is a Poland-based pharmaceutical and life science company specializing in the research, development, and commercialization of products and technologies derived from scientific research, particularly in the areas of healthy aging, bioscience, and topical technologies. The Company is structured around research and development activities focused on the biological and therapeutic potential of 1-methylnicotinamide (1-MNA), a naturally occurring metabolite of niacin, and develops dietary supplements, health-related products, and drug candidates based on this technology. The Company's core activity centers on the application of 1-MNA technology, including products marketed under the Endotelio and Menavitin product lines. The Company conducts research in cooperation with academic institutions and research centers and supports its activities through patent protection and commercialization of developed technologies in domestic and international markets.
Financial Summary: BRIEF: For the six months ended 30 June 2026, Pharmena SA revenues decreased 15% to PLN663K. Net loss increased 24% to PLN1.5M. Revenues reflect Other countries segment decrease of 17% to PLN498K, Poland segment decrease of 8% to PLN165K. Higher net loss reflects Total Financial Income decrease of 66% to PLN125K (income), Other Operating Income decrease of 65% to PLN6K (income).